NCT05189886

Brief Summary

In this study, the investigators evaluate whether routine double inflation of the valve could have a lasting impact. The investigators hypothesize that a routine second reinflation of the balloon, or "double tap", will improve flow across the valve when compared to a single inflation. The investigators hypothesize that "double tap" (1) will decrease mean gradient between first and second inflation during the procedure, (2) will decrease mean gradient on immediate post procedure and 30 day postprocedure echocardiograms when compared to mean gradient gradient after single inflation. Less obstruction indicated by lower mean gradient early after deployment may translate to improved 5 and 10 year outcomes. Furthermore, the investigators hypothesize that this small change in technique will have no effect on procedure time or complications and the change will not result in any increase in perioperative vascular complications, or new permanent pacemaker insertion. The primary objective of this study is to determine if double valve inflation during a TAVR procedure improves valve area and mean gradients as measured by echocardiogram immediately following the procedure and at 30 days follow up.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 10, 2021

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

November 22, 2021

Completed
2 months until next milestone

First Posted

Study publicly available on registry

January 13, 2022

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

January 13, 2022

Status Verified

December 1, 2021

Enrollment Period

2.1 years

First QC Date

November 22, 2021

Last Update Submit

December 28, 2021

Conditions

Keywords

TAVRBalloon Valvuloplasty

Outcome Measures

Primary Outcomes (4)

  • Valve area

    Valve area as measured by echocardiogram

    Immediately following the procedure

  • Valve area

    Valve area as measured by echocardiogram

    At 30 days follow up

  • Mean gradient

    Mean gradient as measured by echocardiogram

    Immediately following the procedure

  • Mean gradient

    Mean gradient as measured by echocardiogram

    At 30 days follow up

Study Arms (2)

Prospective

The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.

Procedure: Double Balloon Valvuloplasty in TAVR

Retrospective

The retrospective phase will collect data from previous TAVR procedures completed between February 2019 and October 1, 2021. Data from up to 200 patient charts will be collected using the Society of Thoracic Surgeons/American College of Cardiology that is maintained by the CMH Cardiology Department. The population will be de-identified as the purpose is to obtain descriptive information from the medical records to utilize for propensity match scoring.

Interventions

The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.

Prospective

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A patient with moderate to severe aortic regurgitation requiring replacement of his/her aortic valve.

You may qualify if:

  • Male or female ≥18 years of age
  • Diagnosis of severe native valve aortic stenosis
  • Meets the standard of care indications to undergo TAVR procedure (aortic valve area \<1.0 cm2 or mean pressure gradient \>40 mmHg or peak velocity \>4.0 m/s or aortic valve area index \<0.6).
  • Provided informed consent.

You may not qualify if:

  • History of prior aortic valve replacement
  • Pre-existing moderate to severe aortic regurgitation
  • Lacking pre-procedure echocardiogram
  • Patients planning to undergo multiple valve replacements simultaneously
  • Intraoperative arrhythmia
  • Intraoperative hemodynamic instability
  • Intraoperative complication during initial inflation (such as: aortic dissection, coronary artery occlusion, coronary artery dissection)
  • At the discretion of the principal investigator, any reason that the potential subject may be unfit for participation, such as frailty.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Community Memorial Hospital

Ventura, California, 93003, United States

RECRUITING

MeSH Terms

Conditions

Aortic Valve Stenosis

Condition Hierarchy (Ancestors)

Aortic Valve DiseaseHeart Valve DiseasesHeart DiseasesCardiovascular DiseasesVentricular Outflow Obstruction

Study Officials

  • Jennifer Wan, MD

    Community Memorial HealthCenter

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending Physician

Study Record Dates

First Submitted

November 22, 2021

First Posted

January 13, 2022

Study Start

November 10, 2021

Primary Completion

December 1, 2023

Study Completion

December 1, 2024

Last Updated

January 13, 2022

Record last verified: 2021-12

Locations